MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation

A review of PARP inhibitors: from bench to bedside

(2010) C. Underhill et al.   ANNALS OF ONCOLOGY

Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors

(2010) E. V. Efimova et al.   CANCER RESEARCH

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers

(2010) C. Powell et al.   CANCER TREATMENT REVIEWS

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

(2009) A. L. Russo et al.   CLINICAL CANCER RESEARCH

Poly(ADP-ribose) polymerase: a new therapeutic target?

(2009) Domokos Gerö et al.   Current Opinion in Anesthesiology

PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases

(2009) Andreína Peralta-Leal et al.   FREE RADICAL BIOLOGY AND MEDICINE

Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

(2009) Philip Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

(2009) F. A. Dungey et al.   MOLECULAR CANCER THERAPEUTICS

Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential

(2008) Fiona A. Dungey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS